Across TCGA pan-cancer cohorts, NUDT11 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of NUDT11’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where NUDT11 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types NUDT11 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

PDAC, HNSC, and LSCC are the cancer types where NUDT11 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NUDT11 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	−1.462	<.001	6	view →
HNSC	All	All	−0.867	.007	6	view →
LSCC	Male	II,III,IV	+0.882	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: NUDT11 RNA expression & survival · all NUDT11 data types